Bhumibol Adulyadej Hospital, Royal Thai Air Force, Klong thanon, Saimai, Bangkok, Thailand.
Faculty of Medicine, Mahasarakham University, Maha Sarakham, Thailand.
Eur J Clin Nutr. 2018 Mar;72(3):381-387. doi: 10.1038/s41430-017-0033-6. Epub 2017 Nov 21.
BACKGROUND/OBJECTIVES: Sarcopenia is associated with increased mortality. European and North American recommended screening for low muscle mass uses gender specific cut points, with no adjustment for ethnicity. We wished to determine whether the prevalence of sarcopenia was altered by ethnicity in peritoneal dialysis (PD) patients.
SUBJECTS/METHODS: We measured appendicular lean mass indexed to height (ALMI) in PD patients by segmental bioimpedance and determined sarcopenia using different cut off points for reduced muscle mass.
We measured ALMI in 434 PD patients, 55.1% males, mean age 55.3 ± 16.2 years, 32.3% diabetic, 54.1% white, 23.7% Asian, 19.1% black. ALMI was lower in Asian women, compared to white and black women (6.4 ± 1.1 vs. 6.6 ± 1.0 and 6.9 ± 1.4 kg/m), and lower in Asian men (7.5 ± 1.3 vs. 8.5 ± 1.2 and 8.7 ± 1.3 kg/m), p < 0.001. Depending on the ALM/ALMI cut point; the prevalence of sarcopenia was greater in Asian patients (25.6-41.2% using North American or European cut points) compared to white (12.3-18.7%) and black patients (3.8-15.7%), p < 0.001, but <11% when using Asian-specific cut points. The prevalence of sarcopenia obesity (BMI ≥ 30 kg/m) was <3%, for all groups. There was no association with duration of PD, dialysis prescription, residual renal function or small solute clearances.
There is no universally agreed consensus definition for loss of muscle mass (sarcopenia) and current European and North American recommended cut points for screening are adjusted only for gender. As body composition differs also with age and ethnicity, then ideally cut points should be based on age, gender and ethnicity normative values.
背景/目的:肌少症与死亡率增加有关。欧洲和北美的建议筛查方案使用了特定性别的肌肉质量切点,而未针对种族进行调整。我们希望确定在腹膜透析(PD)患者中,种族是否会改变肌少症的患病率。
我们通过节段生物电阻抗法测量 PD 患者的四肢瘦体重指数(ALMI),并使用不同的肌肉质量切点来确定肌少症。
我们测量了 434 名 PD 患者的 ALMI,其中 55.1%为男性,平均年龄为 55.3±16.2 岁,32.3%为糖尿病患者,54.1%为白人,23.7%为亚洲人,19.1%为黑人。与白人女性和黑人女性相比,亚洲女性的 ALMI 较低(6.4±1.1 与 6.6±1.0 和 6.9±1.4 kg/m),而亚洲男性的 ALMI 也较低(7.5±1.3 与 8.5±1.2 和 8.7±1.3 kg/m),p 值均<0.001。根据 ALM/ALMI 切点的不同,亚洲患者的肌少症患病率(使用北美或欧洲切点为 25.6%-41.2%)高于白人(12.3%-18.7%)和黑人患者(3.8%-15.7%),p 值均<0.001,但使用亚洲特有的切点时<11%。所有组的肌少症肥胖(BMI≥30 kg/m)患病率均<3%。肌少症与 PD 持续时间、透析处方、残余肾功能或小溶质清除率无关。
目前尚无关于肌肉质量损失(肌少症)的通用共识定义,并且欧洲和北美的建议筛查切点仅针对性别进行了调整。由于身体成分也随年龄和种族而不同,因此理想情况下切点应基于年龄、性别和种族的正常值。